Ikena Oncology, Inc.

NasdaqGM:IKNA Rapporto sulle azioni

Cap. di mercato: US$81.1m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Ikena Oncology Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Mark Manfredi

Amministratore delegato

US$1.2m

Compenso totale

Percentuale dello stipendio del CEO45.9%
Mandato del CEO6.7yrs
Proprietà del CEOn/a
Durata media del management1.2yrs
Durata media del Consiglio di amministrazione3.8yrs

Aggiornamenti recenti sulla gestione

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Jun 01
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Jun 01
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Aug 15
Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

May 20
Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

Apr 29
Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Jan 06
We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Aug 06
Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Mar 23
Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 21
Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

Feb 19
Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Nov 02
We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

Jul 13
Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mark Manfredi rispetto agli utili di Ikena Oncology?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$70m

Dec 31 2023US$1mUS$569k

-US$68m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$546k

-US$69m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$5mUS$530k

-US$34m

Sep 30 2021n/an/a

-US$63m

Jun 30 2021n/an/a

-US$55m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$606kUS$410k

-US$44m

Compensazione vs Mercato: La retribuzione totale di Mark ($USD 1.24M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Mark è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Mark Manfredi (53 yo)

6.7yrs

Mandato

US$1,240,640

Compensazione

Dr. Mark Manfredi, Ph D., serves as Member of Scientific Advisory Board of Bantam Pharmaceutical, LLC. He has been President, Chief Executive Officer and Director of Ikena Oncology, Inc. since December 201...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Mark Manfredi
President6.7yrsUS$1.24mNessun dato
Jotin Marango
COO, CFO & Head of Corporate Development2.3yrsUS$782.32k0%
$ 0
Rebecca Cohen
Vice President of Investor Relationsless than a yearNessun datoNessun dato
Jeffrey Ecsedy
Chief Development Officer2.8yrsNessun datoNessun dato
Navin Parwani
VP & Head of Quality1.6yrsNessun datoNessun dato
Bob Lally
Senior Vice President of Finance & Operationsno dataNessun datoNessun dato
David Damphousse
Senior Vice President of Clinical Development Operationsless than a yearNessun datoNessun dato
Caroline Germa
Chief Medical Officerless than a yearNessun datoNessun dato
Valdas Jurkauskas
Senior Vice President of Technical Operationsless than a yearNessun datoNessun dato

1.2yrs

Durata media

52.5yo

Età media

Gestione esperta: Il team dirigenziale di IKNA non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Mark Manfredi
President6.7yrsUS$1.24mNessun dato
Jean-Francois Formela
Independent Director8.4yrsUS$130.36k0%
$ 0
George Demetri
Chair of Scientific Advisory Board3.8yrsNessun datoNessun dato
Otello Stampacchia
Independent Director3.7yrsUS$128.25k0%
$ 0
Neal Rosen
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Kevan Shokat
Member of Scientific Advisory Board3.8yrsNessun datoNessun dato
Owen Hughes
Chairman of the Board1.6yrsUS$167.86k0%
$ 0
David Bonita
Independent Director8.4yrsUS$131.86k0%
$ 0
Iain Dukes
Independent Director7.8yrsUS$126.97k0%
$ 0
Richard Wooster
Independent Director2.6yrsUS$117.86k0%
$ 0
Josep Tabernero Caturla
Member of Scientific Advisory Board3.8yrsNessun datoNessun dato
Maria Koehler
Independent Director3.3yrsUS$117.86k0%
$ 0

3.8yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IKNA sono considerati esperti (durata media dell'incarico 3.8 anni).